MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria Reports Positive Initial Safety Results for Groundbreaking PfSPZ-LARC2 Malaria Vaccine
Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria® PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.
A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria
Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose. This innovative approach leverages decades of research and cutting-edge genetic engineering to combat one of the world’s deadliest diseases.
Sanaria’s CEO, Dr. Stephen L. Hoffman awarded the Walter Reed Medal at the American Society of Tropical Medicine’s Annual Conference
The Walter Reed Medal is awarded every year to recognize distinguished accomplishments in the field of tropical medicine.
International PfSPZ Consortium Met in New Orleans on November 11th & 12th, 2024
On November 11th and 12th, 2024, the International PfSPZ Consortium (i-PfSPZ-C) meeting was held as a hybrid event with members joining both virtually and in-person at the Tulane University, Celia Scott Weatherhead School of Public Health and Tropical Medicine located in downtown New Orleans, Louisiana.
Employee of the Month: Tint Wai
The Sanaria employee of the month for August 2024 is Tint T. Wai. Tint was nominated for her work quality and work ethic.
Sanaria’s Recent Lancet ID Publication Featured in devex Article
Sanaria's recent publication in the Lancet Infectious Diseases was featured in an devex article entitled "The long road to a malaria vaccine that’s safe during pregnancy." This piece highlights the outstanding efficacy and safety over two years in Malian women of childbearing potential including protection during pregnancy - without a booster dose!
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.